Catalyst Event
Pfizer Inc (PFE) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
4/29/2026, 12:00:00 AM
Pfizer announced on April 29, 2026, that its blood-cancer drug Elrexfio met its primary endpoint in a Phase 3 study, significantly improving progression-free survival in patients with relapsed or refractory multiple myeloma.
Korean Translation
2026년 4월 29일, 화이자는 혈액암 치료제 엘렉스피오(Elrexfio)가 3상 임상시험에서 1차 평가변수를 충족하여 재발성 또는 불응성 다발성 골수종 환자의 무진행 생존기간을 유의미하게 개선했다고 발표함.
Related Recent Events
WuXi Biologics (Cayman) Inc (2269) · Other
The U.S. Office of Management and Budget (OMB) is scheduled to publish a full list of 'biotechnology companies of concern' (BCCs) by December 18, 2026, under the BIOSECURE Act; High importance is justified by the potential for severe regulatory risk causing a >10% price impact scheduled.
12/18/2026, 12:00:00 AM
WuXi AppTec Co Ltd (2359) · Other
Ex-dividend date on May 13, 2026, for the 2025 final cash dividend of RMB 1.57927 per share (RMB 15.7927 per 10 shares); low impact estimated as price typically adjusts by the dividend amount, scheduled.
5/13/2026, 12:00:00 AM
Gilead Sciences Inc (GILD) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-07. This event is estimated to have a high price impact as quarterly results often drive significant market volatility scheduled.
5/7/2026, 12:00:00 AM
Kenvue Inc (KVUE) · Earnings Release
Kenvue will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Based on historical earnings volatility, a 5% price impact is expected.
5/7/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer is scheduled to release its Q1 2026 earnings results before the market opens on May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM
Vertex Pharmaceuticals Inc (VRTX) · Earnings Release
Vertex Pharmaceuticals is scheduled to announce its first-quarter 2026 financial results after the market closes on May 4, 2026. This earnings release is estimated to have a >=5% price impact, scheduled
5/4/2026, 12:00:00 AM